Replimune Group, Inc. Banner Image

Replimune Group, Inc.

  • Ticker REPL
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Replimune Group, Inc. Logo Image
  • 51-200 Employees
  • Based in Woburn, Massachusetts
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune’sMore Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical development in combination with other immuno-oncology products with complementary mechanisms of action.
4.7 / 5.0 (124)

Replimune Group, Inc. reports have an aggregate usefulness score of 4.7 based on 124 reviews.

Replimune Group, Inc.

Most Recent Annual Report

Replimune Group, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Replimune Group, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!